Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2017 May 17

PMID 28508145

Citations 11

Authors

Georgia M Beasley

Yinin Hu

Linda Youngwirth

Randall P Scheri

April K Salama

Kara Rossfeld

Syed Gardezi

Doreen M Agnese

J Harrison Howard

Douglas S Tyler

Craig L Slingluff Jr

Alicia M Terando

Affiliations

Soon will be listed here.

Abstract

Background: Sentinel lymph node biopsy (SLNB) is routinely performed for primary cutaneous melanomas; however, limited data exist for SLNB after locally recurrent (LR) or in-transit (IT) melanoma.

Methods: Data from three centers performing SLNB for LR/IT melanoma (1997 to the present) were reviewed, with the aim of assessing (1) success rate; (2) SLNB positivity; and (3) prognostic value of SLNB in this population.

Results: The study cohort included 107 patients. Management of the primary melanoma included prior SLNB for 56 patients (52%), of whom 10 (18%) were positive and 12 had complete lymph node dissections (CLNDs). In the present study, SLNB was performed for IT disease (48/107, 45%) or LR melanoma (59/107, 55%). A sentinel lymph node (SLN) was removed in 96% (103/107) of cases. Nodes were not removed for four patients due to lymphoscintigraphy failures (2) or nodes not found during surgery (2). SLNB was positive in 41 patients (40%, 95% confidence interval (CI) 31.5-50.5), of whom 35 (88%) had CLND, with 13 (37%) having positive nonsentinel nodes. Median time to disease progression after LR/IT metastasis was 1.4 years (95% CI 0.75-2.0) for patients with a positive SLNB, and 5.9 years (95% CI 1.7-10.2) in SLNB-negative patients (p = 0.18). There was a trend towards improved overall survival for patients with a negative SLNB (p = 0.06).

Conclusion: SLNB can be successful in patients with LR/IT melanoma, even if prior SLNB was performed. In this population, the rates of SLNB positivity and nonsentinel node metastases were 40% and 37%, respectively. SLNB may guide management and prognosis after LR/IT disease.

Citing Articles

Great Debate: Limb Infusion for Melanoma: A Thing of the Past?.

Rhodin K, Tyler D, Zager J, Beasley G Ann Surg Oncol. 2023; 30(11):6319-6324.

PMID: 37458946 DOI: 10.1245/s10434-023-13765-0.

The Evolution of the Sentinel Node Biopsy in Melanoma.

Allard-Coutu A, Dobson V, Schmitz E, Shah H, Nessim C Life (Basel). 2023; 13(2).

PMID: 36836846 PMC: 9966203. DOI: 10.3390/life13020489.

Evaluation of Preoperative and Intraoperative Mobile Gamma Camera Imaging in Sentinel Lymph Node Biopsy for Melanoma Independent of Preoperative Lymphoscintigraphy.

Judge J, Popovic K, Petroni G, Kross B, McKisson J, McKisson J J Surg Res. 2023; 285:176-186.

PMID: 36682343 PMC: 11283632. DOI: 10.1016/j.jss.2022.12.013.

In-transit metastatic cutaneous melanoma: current management and future directions.

Patel A, Carr M, Sun J, Zager J Clin Exp Metastasis. 2021; 39(1):201-211.

PMID: 33999365 DOI: 10.1007/s10585-021-10100-3.

Tc-labeled nanocolloid drugs: development methods.

Sadkin V, Skuridin V, Nesterov E, Stasyuk E, Rogov A, Varlamova N Sci Rep. 2020; 10(1):14013.

PMID: 32814811 PMC: 7438322. DOI: 10.1038/s41598-020-70991-2.

References

Morton D, Thompson J, Cochran A, Mozzillo N, Elashoff R, Essner R . Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006; 355(13):1307-17. DOI: 10.1056/NEJMoa060992. View

Faries M, Thompson J, Cochran A, Elashoff R, Glass E, Mozzillo N . The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol. 2010; 17(12):3324-9. PMC: 2970739. DOI: 10.1245/s10434-010-1203-0. View

Pawlik T, Ross M, Johnson M, Schacherer C, McClain D, Mansfield P . Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005; 12(8):587-96. DOI: 10.1245/ASO.2005.05.025. View

Hu Y, Melmer P, Slingluff Jr C . Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye. Ann Surg. 2015; 263(3):588-92. PMC: 4568173. DOI: 10.1097/SLA.0000000000001187. View

Gonzalez A, Jakub J, Harmsen W, Suman V, Markovic S . Status of the Regional Nodal Basin Remains Highly Prognostic in Melanoma Patients with In-Transit Disease. J Am Coll Surg. 2016; 223(1):77-85.e1. DOI: 10.1016/j.jamcollsurg.2016.03.025. View

Balch C, Soong S, Gershenwald J, Thompson J, Reintgen D, Cascinelli N . Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19(16):3622-34. DOI: 10.1200/JCO.2001.19.16.3622. View

Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C . Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016; 17(6):757-767. DOI: 10.1016/S1470-2045(16)00141-8. View

Morton D . Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis. 2012; 29(7):699-706. PMC: 3463679. DOI: 10.1007/s10585-012-9503-3. View

Wrightson W, Wong S, Edwards M, Chao C, Reintgen D, Ross M . Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003; 10(6):676-80. DOI: 10.1245/aso.2003.10.001. View

10.

Morton D, Thompson J, Essner R, Elashoff R, Stern S, Nieweg O . Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999; 230(4):453-63; discussion 463-5. PMC: 1420894. DOI: 10.1097/00000658-199910000-00001. View

11.

Cochran A, Wen D, Huang R, Wang H, Elashoff R, Morton D . Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004; 17(7):747-55. DOI: 10.1038/modpathol.3800117. View

12.

Yao K, Hsueh E, Essner R, Foshag L, Wanek L, Morton D . Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma?. Ann Surg. 2003; 238(5):743-7. PMC: 1356154. DOI: 10.1097/01.sla.0000094440.50547.1d. View

13.

Beasley G, Speicher P, Sharma K, Seigler H, Salama A, Mosca P . Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. J Am Coll Surg. 2014; 218(4):686-92. PMC: 5817639. DOI: 10.1016/j.jamcollsurg.2013.12.025. View

14.

Morton D, Cochran A, Thompson J . Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg. 2007; 245(5):828-9. PMC: 1877075. DOI: 10.1097/01.sla.0000261157.79250.16. View

15.

Coit D, Thompson J, Andtbacka R, Anker C, Bichakjian C, Carson 3rd W . Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014; 12(5):621-9. DOI: 10.6004/jnccn.2014.0066. View

16.

Grunhagen D, Brunstein F, Graveland W, van Geel A, de Wilt J, Eggermont A . One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg. 2004; 240(6):939-47. PMC: 1356509. DOI: 10.1097/01.sla.0000146147.89667.ed. View

17.

Read R, Haydu L, Saw R, Quinn M, Shannon K, Spillane A . In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2014; 22(2):475-81. DOI: 10.1245/s10434-014-4100-0. View

18.

Harlow S, Krag D, Ashikaga T, Weaver D, Meijer S, Loggie B . Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res. 2001; 11(1):45-55. DOI: 10.1097/00008390-200102000-00006. View

19.

Gipponi M, Solari N, Giovinazzo D, Queirolo P, Bertoglio S, Villa G . The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma. Anticancer Res. 2014; 34(6):3197-203. View

20.

McMasters K, Reintgen D, Ross M, Wong S, Gershenwald J, Krag D . Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed?. Ann Surg Oncol. 2001; 8(3):192-7. DOI: 10.1007/s10434-001-0192-4. View